NasdaqGM:TVTXBiotechs
Travere Therapeutics (TVTX) Is Up 14.0% After FDA Focus Shifts To FILSPARI FSGS Label Expansion - Has The Bull Case Changed?
Travere Therapeutics is drawing fresh attention after traders reacted to the upcoming April 13, 2026 FDA PDUFA decision on a supplemental filing for its rare kidney disease drug FILSPARI in focal segmental glomerulosclerosis, alongside a recent analyst upgrade to a Buy rating.
This combination of a potential label expansion in an area with limited treatment options and an improved analyst stance is sharpening focus on how central FILSPARI has become to Travere’s rare disease strategy.
We’ll...